08.13.24 -- 9 Common Tech Transfer Pitfalls To Avoid

Review four key factors for improving on-time delivery when outsourcing drug product manufacturing and discover how investing in building a solid relationship with your CDMO improves timelines.

By partnering with a trusted company that offers expertise in navigating the challenges of scale up, drug developers can have confidence in their ability to successfully bring their products to market.

Allogeneic therapies are gaining popularity due to diversity, scalability, and affordability. A partner with innovative solutions can help streamline the path from discovery to commercialization.

Find out how a strategic partnership with a used equipment dealer can provide guidance through the process of a merger or acquisition of manufacturing facilities and simplify equipment removal and sales.

The current geopolitical climate is leading drug developers to consider global manufacturing partnerships strategically. Identify a CDMO partner that will help protect your IP, save money, and mitigate risk.

A CDMO can augment your capacity and expertise, refine your processes, and ultimately shorten your time to market. Explore best practices that make working with a CDMO as efficient as possible.

Review a CDMO's strategy for overcoming challenges when acquiring new equipment for an Emergency Use Authorization (EUA) project and how leveraging existing resources and collaboration was key.

Explore the benefits of working with a CDMO that has extensive plasmid experience and integrated project teams across the production process.

Explore the benefits of using mRNA for vaccines and therapeutics, and learn how to address technical, intellectual property, and cost considerations when considering commercial production.

Choosing the CDMO best suited to manufacture your rare disease therapy can be challenging. Ideally, a CDMO will prioritize your goals while working to ensure quality and regulatory success.

Asher Biotherapeutics was seeking a CDMO that could handle Phase 2 through to commercial production, as well as taking early-stage projects in its pipeline all the way through their lifecycle.

Explore how utilizing technologies like AI and digital twinning can inform decision-making at the R&D stage and how to optimize the delivery of the final drug product to patients with greener logistics.

While the Brisbane facility’s key value is facilitating development and industrialization of new bacterial strains, how this is accomplished separates it from would-be competitors.

Unlike traditional drugs, AAV therapies require extensive characterization and testing, demanding varying degrees of analysis at each stage of development.